Short Interest in The Oncology Institute, Inc. (NASDAQ:TOI) Increases By 70.1%

The Oncology Institute, Inc. (NASDAQ:TOI) was the target of a large increase in short interest in November. As of November 15th, there was short interest totalling 421,900 shares, an increase of 70.1% from the October 31st total of 248,000 shares. Based on an average trading volume of 1,010,000 shares, the short-interest ratio is currently 0.4 days. Approximately 1.1% of the company’s stock are sold short.

Institutional Investors Weigh In On Oncology Institute

Hedge funds have recently made changes to their positions in the business. HighTower Advisors LLC raised its stake in shares of Oncology Institute by 190.8% during the 3rd quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock worth $27,000 after purchasing an additional 53,382 shares during the period. Renaissance Technologies LLC raised its stake in shares of Oncology Institute by 142.3% during the 2nd quarter. Renaissance Technologies LLC now owns 339,400 shares of the company’s stock worth $156,000 after purchasing an additional 199,300 shares during the period. Finally, Tiff Advisory Services LLC raised its stake in shares of Oncology Institute by 235.1% during the 2nd quarter. Tiff Advisory Services LLC now owns 1,418,685 shares of the company’s stock worth $653,000 after purchasing an additional 995,280 shares during the period. 36.86% of the stock is currently owned by institutional investors.

Oncology Institute Price Performance

Shares of NASDAQ:TOI opened at $0.17 on Thursday. The stock has a market cap of $12.85 million, a PE ratio of -0.22 and a beta of 0.60. Oncology Institute has a 1-year low of $0.13 and a 1-year high of $2.50. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 5.91. The stock’s fifty day simple moving average is $0.29 and its two-hundred day simple moving average is $0.40.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.